Q1 2025 EPS Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT) Lifted by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research increased their Q1 2025 earnings estimates for Corcept Therapeutics in a research report issued to clients and investors on Monday, September 16th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings per share of $0.27 for the quarter, up from their previous estimate of $0.26. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.10 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.31 EPS, Q3 2025 earnings at $0.36 EPS, Q4 2025 earnings at $0.44 EPS, FY2025 earnings at $1.38 EPS and Q2 2026 earnings at $0.53 EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Monday, July 29th. The biotechnology company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.09. Corcept Therapeutics had a net margin of 21.93% and a return on equity of 23.66%. The business had revenue of $163.80 million during the quarter, compared to the consensus estimate of $155.14 million. During the same quarter last year, the firm earned $0.25 earnings per share. Corcept Therapeutics’s quarterly revenue was up 39.1% on a year-over-year basis.

A number of other equities research analysts have also recently commented on CORT. Piper Sandler raised their price target on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday. Truist Financial restated a “buy” rating and issued a $65.00 price target on shares of Corcept Therapeutics in a report on Monday, June 17th. HC Wainwright raised their price target on shares of Corcept Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, July 30th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $38.00 price objective on shares of Corcept Therapeutics in a report on Tuesday, July 30th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Corcept Therapeutics presently has an average rating of “Buy” and an average target price of $53.75.

Corcept Therapeutics Trading Up 6.4 %

NASDAQ:CORT opened at $42.27 on Thursday. The stock has a market capitalization of $4.40 billion, a price-to-earnings ratio of 39.88 and a beta of 0.45. The firm has a fifty day simple moving average of $34.97 and a two-hundred day simple moving average of $29.79. Corcept Therapeutics has a 12 month low of $20.84 and a 12 month high of $43.32.

Institutional Trading of Corcept Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CORT. GAMMA Investing LLC raised its position in shares of Corcept Therapeutics by 90.6% in the first quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 579 shares during the period. Park Place Capital Corp bought a new stake in shares of Corcept Therapeutics in the second quarter valued at approximately $32,000. Atwood & Palmer Inc. bought a new stake in shares of Corcept Therapeutics in the second quarter valued at approximately $35,000. FinTrust Capital Advisors LLC grew its stake in Corcept Therapeutics by 318.7% during the first quarter. FinTrust Capital Advisors LLC now owns 1,771 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 1,348 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its stake in Corcept Therapeutics by 27.0% during the fourth quarter. Quadrant Capital Group LLC now owns 2,107 shares of the biotechnology company’s stock valued at $68,000 after acquiring an additional 448 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

Insider Activity at Corcept Therapeutics

In related news, insider William Guyer sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $35.30, for a total transaction of $353,000.00. Following the transaction, the insider now directly owns 6,039 shares of the company’s stock, valued at $213,176.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Corcept Therapeutics news, insider Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $32.49, for a total value of $162,450.00. Following the sale, the insider now owns 9,290 shares of the company’s stock, valued at $301,832.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider William Guyer sold 10,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $35.30, for a total transaction of $353,000.00. Following the completion of the sale, the insider now directly owns 6,039 shares in the company, valued at approximately $213,176.70. The disclosure for this sale can be found here. Insiders have sold 30,451 shares of company stock valued at $1,090,844 over the last ninety days. Corporate insiders own 20.50% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.